健择化疗治疗卵巢癌和宫颈癌35例临床分析

Clinical Analysis of Gemcitabine in The Treatment for 35 Cases with Ovarian and Cervical Carcinoma

[目的]研究健择化疗治疗妇科肿瘤的临床疗效和毒副反应.[方法]采用健择单药或联合化疗治疗7例宫颈癌和28例上皮性卵巢癌.[结果]35例患者健择化疗总有效率为57.1%,其中宫颈癌85.7%、初治卵巢癌72.7%、复发性卵巢癌35.2%.单药治疗有效率40.0%,联合治疗63.3%.中位缓解期10个月.主要毒副反应为血液毒性,以白细胞下降为主,其中Ⅲ～Ⅳ级11.4%,恢复较快.消化道反应、脱发、肝肾功能损伤、发热等均较轻.[结论]健择是治疗妇科肿瘤较安全且有一定疗效的抗癌药物,其联合用药可提高疗效,是复发和耐药性卵巢癌治疗较好选择之一.

To evaluate the clinical efficacy and toxicity o f gemcitabine in gynecological malignan-cies.Seven patients with stageⅡ cervical cancer and28patients with advanced ovarian cancer were treated by singl e or combination chemotherapy of gemcitabine.The overall response rate was57.1%,in which85.7%for cervical cancer,72.7%for primary ovarian cancer and35. 2%for recurrent ovar-ian cancer.The response rate treated by combination chemot herapy(63.3%)was higher than that treated by single(40.0%).The medium free-prog ress-period was10months.The main toxicity was hematological toxic-ity,while n on-hematological toxicity was mild and tolerable.[Conclusion]Gemcitabine is eff ective in the treat-ment for gynecologic malignancies with modest side effects, and may be one of the better choices for recur-rent or resistant ovarian cancer .